Market Research Logo

Osteogenesis Imperfecta - Pipeline Review, H2 2018

Osteogenesis Imperfecta - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteogenesis Imperfecta - Pipeline Review, H2 2018, provides an overview of the Osteogenesis Imperfecta (Genetic Disorders) pipeline landscape.

Osteogenesis imperfecta (OI) is a group of genetic disorders that mainly affect the bones. Mutations in the COL1A1, COL1A2, CRTAP, and P3H1 genes cause OI. An imbalance between the action of osteoclasts and osteoblasts was found in OI.  Symptoms include short stature, brittle teeth, hearing loss, bone deformities and triangular-shaped face. Treatment includes medication like bisphosphonates, exercises and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteogenesis Imperfecta - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Osteogenesis Imperfecta (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteogenesis Imperfecta (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteogenesis Imperfecta and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 2 and 1 respectively.

Osteogenesis Imperfecta (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteogenesis Imperfecta (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Osteogenesis Imperfecta (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteogenesis Imperfecta (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteogenesis Imperfecta (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteogenesis Imperfecta (Genetic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteogenesis Imperfecta (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteogenesis Imperfecta (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Osteogenesis Imperfecta - Overview
Osteogenesis Imperfecta - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Osteogenesis Imperfecta - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Osteogenesis Imperfecta - Companies Involved in Therapeutics Development
Amgen Inc
Bone Therapeutics SA
Genzyme Corp
Mereo Biopharma Group Plc
Mesentech Inc
SOM Biotech SL
Osteogenesis Imperfecta - Drug Profiles
ALLOB - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Osteogenesis Imperfecta - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fresolimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
setrusumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize EP4 Receptor for Osteoporosis and Osteogenesis Imperfecta - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Osteogenesis Imperfecta - Dormant Projects
Osteogenesis Imperfecta - Discontinued Products
Osteogenesis Imperfecta - Product Development Milestones
Featured News & Press Releases
Nov 13, 2017: Mereo Receives EMA PRIME Designation for BPS-804 to Treat Osteogenesis Imperfecta
May 04, 2017: Initiation of BPS-804 potentially pivotal Phase 2b study in patients with osteogenesis imperfecta, an orphan disease
Feb 20, 2017: Mereo BioPharma: BPS-804 accepted for EMA Adaptive Pathways programme
Jun 30, 2016: Mereo’s BPS-804 granted EU Orphan Drug status for Osteogenesis Imperfecta
Mar 02, 2016: Mereo BPS-804 granted U.S. orphan drug status for osteogenesis imperfecta
Oct 01, 2013: Bone Therapeutics receives clearance for ALLOB phase I/IIa trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Osteogenesis Imperfecta, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Osteogenesis Imperfecta - Pipeline by Amgen Inc, H2 2018
Osteogenesis Imperfecta - Pipeline by Bone Therapeutics SA, H2 2018
Osteogenesis Imperfecta - Pipeline by Genzyme Corp, H2 2018
Osteogenesis Imperfecta - Pipeline by Mereo Biopharma Group Plc, H2 2018
Osteogenesis Imperfecta - Pipeline by Mesentech Inc, H2 2018
Osteogenesis Imperfecta - Pipeline by SOM Biotech SL, H2 2018
Osteogenesis Imperfecta - Dormant Projects, H2 2018
Osteogenesis Imperfecta - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Osteogenesis Imperfecta, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report